1. The Nurse View Key Insights Along the CML Continuum

3. Activity Goals

4. TKIs for the Treatment of CML

5. Role of the Nurse Practitioner

6. Factors Associated With Choice of Frontline Therapy

7. Response Rates With Dasatinib, Nilotinib

8. Sokal and Hasford Risk Factors

9. Factors Influencing Response to Therapy

10. Patient Characteristics Determine TKI Selection

11. Factors Influencing Choice of First-line Therapy

12. Adverse Effects of Imatinib 5-Year Follow-Up

13. Nurse’s Role in Patient Management

14. Adverse Effects of Imatinib 5-Year Follow-Up

15. Adverse Reactions Reported in ≥ 10% of Patients on Dasatinib 100 mg Every Day

16. Selected Adverse Effects With Nilotinib 300 mg Twice a Day

17. Selected Drug-Drug Interactions With TKIs

18. Adverse Effects of Bosutinib and Ponatinib (≥ 20%)

19. Revised Information for Ponatinib

20. Management of TKI Adverse Effects

21. Monitoring Response to Therapy

22. Monitoring Precautions

23. Reasons for Nonadherence

24. Reasons to Switch Therapy

25. Role of Pharmacist in Cancer Care

26. Role of the Nurse/Nurse Practitioner

27. Potential for Treatment Discontinuation

28. STIM Trial Multivariate Analysis

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)

32. References

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)